Pipe

R&D ea Sorrento e tsepamisitse maikutlo ho nts'etsopele ea boqapi ho COVID-19, kalafo ea mofets'e, taolo e felletseng ea bohloko le mafu a autoimmune.

Mananeo a Bohlokwa Tlhaloso Pele ho tlhokomelo Karolo ea I Mothati oa II Mokhahlelo oa III/Bohlokoa FDA Approval
Mananeo a COVID-19  

COVISTIX™ (tlhahlobo) Tlhahlobo e potlakileng ea Antigen

*

Tumello ea Tšebeliso ea Tšohanyetso (EUA) Mexico (COFEPRIS), Brazil (ANVISA), le CE E tšoauoa Europe

COVIMARK™ (tlhahlobo) Tlhahlobo e potlakileng ea Antigen

*

Kopo e rometsoe US le Canada bakeng sa Tumello ea Tšebeliso ea Tšohanyetso (EUA)

COVISHIELD™ (kalafo) Antibody e Neutraizing (IN) ho Bakuli ba ka Ntle le Bakuli ba ka Lapeng

40%*

COVISHIELD™ (kalafo) Antibody e Neutralizing (IV) ho Bakuli ba ka Ntle le Bakuli ba ka Lapeng

20%*

FUJOVEE™ (Abivertinib) COVID-19 e matla ho Bakuli ba ICU

82%*

Teko ea Bohlokoa e Emetseng ho Hlakoloa ha FDA

OQORY™ (COVI-MSC) ARDS ka lebaka la COVID-19 ho Bakuli ba ICU

82%*

Teko ea Bohlokoa Brazil

Mlan Inhibitor (pilisi ea molomo) Khahlano le bongata

40%*

Ente ea Omicron mRNA ente

20%*

Mananeo a Bohlokwa Tlhaloso Pele ho tlhokomelo Karolo ea I Mothati oa II Mokhahlelo oa III/Bohlokoa FDA Approval
immunotherapy  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) B Cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib) Prostate

20%*

FUJOVEE™ (Abivertinib) Lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*Ka Tšebelisano le Lee's Pharm naheng ea China

PD-L1 (STI-3031)** Kankere ea Mokokotlo

82%*

**Naheng ea Amerika le ka kopanelo le ImmuneOncia ea Korea

CD47 Lihlahala tse Tiileng

40%*

CD38 DAR-T Myeloma e ngata

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, le esophageal

40%*

TROP2 ADC* Lihlahala tse Tiileng

40%*

* China

Seprehvec™ oncolytic virus Lihlahala Tse Tiileng; Lihlahala tsa CNS

40%*

BCMA ADC Lihlahala tsa Metsi

20%*

Bevacizumab-ADAB™ Kankere ea Endometrial

40%*

Ka kopanelo le Mayo Clinic

Bevacizumab-ADAB™ Cancer ea kankere ea mahe

40%*

Ka kopanelo le Mayo Clinic

Rituximab-ADAB™ B-cell Lymphomas

40%*

Ka kopanelo le Mayo Clinic
Mananeo a Bohlokwa Tlhaloso Pele ho tlhokomelo Karolo ea I Mothati oa II Mokhahlelo oa III/Bohlokoa FDA Approval
Bohloko  

ZTlido™ 1.8%
Neuralgia ea Postherpetic - PHN

99.8%*

Sp,-102 (SEMDEXA) Bohloko ba Lumbar Radicular / Sciatica

82%*

Sp,-103 (Lidocaine Topical System 5.4%) Mahlaba a Acute Back Back

20%*

Sp,-104 (Naltrexone e Liehisitsoe ho Burst Low) Fibromyalgia

20%*

RTX (resiniferatoxin)
Epidural ente
Bohloko bo ke keng ba Rarolloa ho Kankere e Tsoetseng Pele

60.3%*

Lebitso la khutsana

RTX (resiniferatoxin)
Tsela e ka hare-hare
Bohloko bo Itekanetseng ho isa ho Bohlokoa Knee

60.2%*

Mananeo a Bohlokwa Tlhaloso Pele ho tlhokomelo Karolo ea I Mothati oa II Mokhahlelo oa III/Bohlokoa FDA Approval
Phaliso ea Lymphatic  

Sofusa® -ba khahlanong le TNF Autoimmune (RA)

40%*

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL)

40%*

Sofusa® khahlanong le CTLA-4 Melanoma

40%*

Ka kopanelo le Mayo Clinic
Mananeo a COVID-19
Mananeo a Bohlokwa (Tlhahiso) Phase
COVISTIX™ (tlhahlobo) FDA EUA
COVIMARK™ (tlhahlobo) FDA EUA
COVISHIELD™ (kalafo) PH I
COVISHIELD™ (kalafo) Pele ho tlhokomelo
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpro Inhibitor (pilisi ea molomo) (anti-viral) Ph I
Ente ea Omicron mRNA (ente) Pele ho tlhokomelo
immunotherapy
Mananeo a Bohlokwa (Tlhahiso) Phase
FUJOVEE™ (Abivertinib) (NSCLC) Ph III
FUJOVEE™ (Abivertinib) (B Cell Lymphomas) Ph II
FUJOVEE™ (Abivertinib) (Prostate) Pele ho tlhokomelo
FUJOVEE™ (Abivertinib) (Lupus) Pele ho tlhokomelo
FUJOVEE™ (Abivertinib) (MOF) Pele ho tlhokomelo
FUJOVEE™ (Abivertinib) (GvHD) Pele ho tlhokomelo
PD-L1 (Socazolimab)*(SCLC) Ph III
PD-L1 (STI-3031)** (Kankere ea popelo) Ph III
CD47 (Lihlahala tse tiileng) Ph I
CD38 DAR-T Myeloma e ngata Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, le esophageal) Ph I
TROP2 ADC* (Lihlahala tse tiileng) Ph I
Seprehvec™ oncolytic virus (Lihlahala tse tiileng; CNS Tumors) PH I
BCMA ADC (Lihlahala tsa Metsi) Pele ho tlhokomelo
Bevacizumab-ADAB™ (Kankere ea Endometrial) Ph I
Bevacizumab-ADAB™ (Kankere ea Ovary) Ph I
Rituximab-ADAB™ (B-cell Lymphomas) Ph I
Bohloko
Mananeo a Bohlokwa (Tlhahiso) Phase
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
Sp,-102 (SEMDEXA) Ph III
Sp,-103 (Lidocaine Topical System 5.4%) Pele ho tlhokomelo
Sp,-104 (Naltrexone e Liehisitsoe ho Burst Low) Pele ho tlhokomelo
RTX (resiniferatoxin) Epidural ente (Bohloko bo ke keng ba Batla Kankere e Tsoetseng Pele) Ph II
RTX (resiniferatoxin) Tsela e ka hare-hare (Mahlaba a Knee Mangoleng a Bohareng ho isa ho a Matenya) Ph II
Phaliso ea Lymphatic
Mananeo a Bohlokwa (Tlhahiso) Mothati oa II
Sofusa® -ba khahlanong le TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 T-Cell Lymphoma (CTCL) Ph I
Sofusa® khahlanong le CTLA-4 (Melanoma) Ph I